

# A European randomised multicentre study of interferon alpha-2b versus no treatment after intensive therapy and Autologous hematopoietic Stem Cell Transplantation (ASCT) for relapsing lymphoma patients

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 14/07/2014	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr - -

**Contact details**  
UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**Protocol serial number**  
LY302

## Study information

## Scientific Title

### Study objectives

Not provided at time of registration

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Primary study design

Interventional

### Study design

Randomised controlled trial

### Study type(s)

Not Specified

### Health condition(s) or problem(s) studied

Lymphoma (Hodgkin's), Lymphoma (non-Hodgkin's)

### Interventions

Patients are randomised to one of two treatment groups:

Group A: High dose therapy with ASCT, then after haematologic recovery, no further treatment.

Group B: High dose therapy with ASCT, then after haematologic recovery, interferon alpha-2b 2MU subcutaneously three times weekly for the first four weeks then 3MU three times weekly for 17 months. The interferon dose will be modified according to haematologic tolerance.

### Intervention Type

Other

### Phase

Not Specified

### Primary outcome(s)

Not provided at time of registration

### Key secondary outcome(s)

Not provided at time of registration

### Completion date

01/01/2000

## Eligibility

### Key inclusion criteria

1. Patients with histologically proven non-Hodgkin's lymphoma or Hodgkin's disease, in first relapse or first progression responding to salvage regimen, and treated with high dose therapy and ASCT
2. Normal renal and hepatic function.
3. Eastern Cooperative Oncology Group (ECOG) performance status zero to three
4. Aged 18 to 65 years
5. No history of prior or concomitant malignancy except for treated (surgery or radiotherapy) basal cell carcinoma of the skin or carcinoma in situ, whatever the site

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/1999

**Date of final enrolment**

01/01/2000

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

**Sponsor information**

**Organisation**

Schering-Plough Ltd (UK)

**ROR**

<https://ror.org/00148fb49>

**Funder(s)****Funder type**

Industry

**Funder Name**

Schering-Plough Ltd (UK)

**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration